# OnCo record immuno-oncology (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/immuno-oncology/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "immuno-oncology" ;
  schema:name "Immuno-oncology (IO) and checkpoint blockade"@en ;
  schema:alternateName "I-O"@en, "immuno-oncology"@en, "checkpoint blockade"@en, "immune checkpoint blockade"@en, "ICB"@en, "ICI"@en, "ICIs"@en, "PD-1 blockade"@en, "PD-(L)1"@en, "PD-(L)1 blockade"@en, "PD-1/PD-L1"@en, "anti-PD-1"@en, "anti-PD-L1"@en, "anti-CTLA-4"@en, "anti-PD(L)1"@en, "chemo-IO"@en, "chemo-immunotherapy"@en, "chemoimmunotherapy"@en, "IO-based"@en, "IO-naive"@en, "post-IO"@en, "IO-refractory"@en, "immunotherapy-refractory"@en, "immunotherapy-resistant"@en, "dual checkpoint blockade"@en, "dual immune checkpoint blockade"@en, "IO combination"@en, "IO + chemo"@en ;
  schema:description "Treatments that take the brakes off the patient's own immune system so it attacks the cancer, chiefly antibodies against PD-1, PD-L1 and CTLA-4. 'IO' is industry shorthand; 'chemo-IO' means chemotherapy plus a checkpoint inhibitor, the commonest first-line combination."@en ;
  schema:url <https://onco.cc/terms/immuno-oncology/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Immune_checkpoint_inhibitor> ;
  schema:citation <https://en.wikipedia.org/wiki/Immune_checkpoint_inhibitor> ;
  onco:related <https://onco.cc/terms/irae/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/mss-pmmr/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/atezolizumab/> .